Literature DB >> 17384215

Comprehensive arrayed primer extension array for the detection of 59 sequence variants in 15 conditions prevalent among the (Ashkenazi) Jewish population.

Iris Schrijver1, Maigi Külm, Phyllis I Gardner, Eugene P Pergament, Morris B Fiddler.   

Abstract

In the Ashkenazi Jewish population, serious and lethal genetic conditions occur with relatively high frequency. A single test that encompasses the majority of population-specific mutations is not currently available. For comprehensive carrier screening and molecular diagnostic purposes, we developed a population-specific and inclusive microarray. The arrayed primer extension genotyping microarray carries 59 sequence variant detection sites, of which 53 are detectable bi-directionally. These sites represent the most common variants in Tay-Sachs disease, Bloom syndrome, Canavan disease, Niemann-Pick A, familial dysautonomia, torsion dystonia, mucolipidosis type IV, Fanconi anemia, Gaucher disease, factor XI deficiency, glycogen storage disease type 1a, maple syrup urine disease, nonsyndromic sensorineural hearing loss, familial Mediterranean fever, and glycogen storage disease type III. Several mutations in the selected disorders that are not prevalent per se in the Ashkenazi Jewish populations, as well pseudodeficiency alleles, are also included in the array. The initial technical evaluation of this microarray demonstrates that it is comprehensive, robust, sensitive, specific, and easily modifiable. This cost-effective array is based on a diversely applied platform technology and is suitable for both carrier screening and disease detection in Ashkenazi and Sephardic Jewish populations.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17384215      PMCID: PMC1867437          DOI: 10.2353/jmoldx.2007.060100

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  40 in total

1.  Arrayed primer extension: solid-phase four-color DNA resequencing and mutation detection technology.

Authors:  A Kurg; N Tõnisson; I Georgiou; J Shumaker; J Tollett; A Metspalu
Journal:  Genet Test       Date:  2000

2.  Unravelling genetic data by arrayed primer extension.

Authors:  N Tõnisson; A Kurg; K Kaasik; E Lõhmussaar; A Metspalu
Journal:  Clin Chem Lab Med       Date:  2000-02       Impact factor: 3.694

3.  Mucolipidosis type IV: novel MCOLN1 mutations in Jewish and non-Jewish patients and the frequency of the disease in the Ashkenazi Jewish population.

Authors:  R Bargal; N Avidan; T Olender; E Ben Asher; M Zeigler; A Raas-Rothschild; A Frumkin; O Ben-Yoseph; Y Friedlender; D Lancet; G Bach
Journal:  Hum Mutat       Date:  2001-05       Impact factor: 4.878

Review 4.  A genetic profile of contemporary Jewish populations.

Authors:  H Ostrer
Journal:  Nat Rev Genet       Date:  2001-11       Impact factor: 53.242

5.  Gaucher disease: the origins of the Ashkenazi Jewish N370S and 84GG acid beta-glucosidase mutations.

Authors:  G A Diaz; B D Gelb; N Risch; T G Nygaard; A Frisch; I J Cohen; C S Miranda; O Amaral; I Maire; L Poenaru; C Caillaud; M Weizberg; P Mistry; R J Desnick
Journal:  Am J Hum Genet       Date:  2000-04-21       Impact factor: 11.025

6.  Identification of the gene causing mucolipidosis type IV.

Authors:  R Bargal; N Avidan; E Ben-Asher; Z Olender; M Zeigler; A Frumkin; A Raas-Rothschild; G Glusman; D Lancet; G Bach
Journal:  Nat Genet       Date:  2000-09       Impact factor: 38.330

7.  Maple syrup urine disease: identification and carrier-frequency determination of a novel founder mutation in the Ashkenazi Jewish population.

Authors:  L Edelmann; M P Wasserstein; R Kornreich; C Sansaricq; S E Snyderman; G A Diaz
Journal:  Am J Hum Genet       Date:  2001-08-16       Impact factor: 11.025

8.  Contribution of connexin 26 mutations to nonsyndromic deafness in Ashkenazi patients and the variable phenotypic effect of the mutation 167delT.

Authors:  I Lerer; M Sagi; E Malamud; H Levi; A Raas-Rothschild; D Abeliovich
Journal:  Am J Med Genet       Date:  2000-11-06

9.  A pseudodeficiency allele common in non-Jewish Tay-Sachs carriers: implications for carrier screening.

Authors:  B L Triggs-Raine; E H Mules; M M Kaback; J S Lim-Steele; C E Dowling; B R Akerman; M R Natowicz; E E Grebner; R Navon; J P Welch
Journal:  Am J Hum Genet       Date:  1992-10       Impact factor: 11.025

10.  Laboratory standards and guidelines for population-based cystic fibrosis carrier screening.

Authors:  W W Grody; G R Cutting; K W Klinger; C S Richards; M S Watson; R J Desnick
Journal:  Genet Med       Date:  2001 Mar-Apr       Impact factor: 8.822

View more
  5 in total

1.  Experience with carrier screening and prenatal diagnosis for 16 Ashkenazi Jewish genetic diseases.

Authors:  Stuart A Scott; Lisa Edelmann; Liu Liu; Minjie Luo; Robert J Desnick; Ruth Kornreich
Journal:  Hum Mutat       Date:  2010-11       Impact factor: 4.878

Review 2.  Therapeutic approaches for neuronopathic lysosomal storage disorders.

Authors:  Raphael Schiffmann
Journal:  J Inherit Metab Dis       Date:  2010-02-17       Impact factor: 4.982

3.  High-density SNP genotyping to define beta-globin locus haplotypes.

Authors:  Li Liu; Shalini Muralidhar; Manisha Singh; Caprice Sylvan; Inderdeep S Kalra; Charles T Quinn; Onyinye C Onyekwere; Betty S Pace
Journal:  Blood Cells Mol Dis       Date:  2008-10-01       Impact factor: 3.039

4.  Multiplex detection and genotyping of point mutations involved in charcot-marie-tooth disease using a hairpin microarray-based assay.

Authors:  Yasser Baaj; Corinne Magdelaine; Virginie Ubertelli; Christophe Valat; Yoanne Mousseau; Hao Qiu; Benoît Funalot; Jean-Michel Vallat; Franck G Sturtz
Journal:  Res Lett Biochem       Date:  2009-06-11

5.  High-throughput carrier screening using TaqMan allelic discrimination.

Authors:  Anastasia Fedick; Jing Su; Chaim Jalas; Lesley Northrop; Batsal Devkota; Josef Ekstein; Nathan R Treff
Journal:  PLoS One       Date:  2013-03-26       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.